| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2024-003 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 关于全资孙公司向公司控股股东借款展期暨关联交 易进展的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 交易简要内容：上海阿拉丁生化科技股份有限公司（以下简称"公 司"）全资孙公司 Aladdin Scientific Corporation（以下简称"美国孙公 司"）与公司控股股东、实际控制人徐久振先生就前期不超过美元 60 万元的 借款额度达成展期约定，借款期限自 2024 年 2 月 19 日到期后延长 12 个月 （即展期至 2025 年 2 月 19 日），展期期间除原定借款期限外，借款额度、 借款利率等其他条件按原约定执行。借款年利率综合参考人民币及美元的银 行同期贷款基准利率，不超过其中较低者。美国孙公司可以根据实际情况在 借款期限及额度内连续循环使用。公司及美国孙公司就本次借 ...

| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2024-001 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 根据相关规定及《上海阿拉丁生化科技股份有限公司向不特定对象发行可转 换公司债券募集说明书》的约定（以下简称"《募集说明书》"），公司本次发行的 "阿拉转债"自 2022 年 9 月 21 日起可转换为公司股份，公司可转债的初始转股 价格为人民币 63.72 元/股。 经中国证券监督管理委员会证监许可〔2022〕72 号文同意注册，公司于 2022 年 3 月 15 日向不特定对象发行了 387.40 万张可转换公司债券，每张面值 100 元，发行总额 38,740.00 万元。发行方式采用向公司在股权登记日（2022 年 3 月 14 日，T-1 日）收市后登记在册的发行人原股东优先配售，原股东优先配售 后余额部分（含 ...

| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2023-045 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 关于不向下修正"阿拉转债"转股价格的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 经中国证券监督管理委员会证监许可〔2022〕72 号文同意注册，公司于 2022 年 3 月 15 日向不特定对象发行了 387.40 万张可转换公司债券，每张面值 100 元，发行总额 38,740.00 万元。 经上海证券交易所自律监管决定书〔2022〕88 号文同意，公司 38,740.00 万元可转换公司债券于 2022 年 4 月 12 日起在上海证券交易所挂牌交易，债券简 称"阿拉转债"，债券代码"118006"。 根据相关规定及《上海阿拉丁生化科技股份有限公司向不特定对象发行可转 换公司债券募集说明书》的约定（以下简称"《募集说明书》"），公司本次发行的 "阿拉转债"自 2022 年 9 月 21 日起可转换 ...

| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2023-044 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 关于"阿拉转债"预计满足转股价格修正条件的提示 性公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 2023 年 11 月 22 日至 2023 年 12 月 5 日，上海阿拉丁生化科技股份有限 公司（以下简称"公司"）股票已有 10 个交易日的收盘价低于当期转股价格的 85%，预计触发转股价格向下修正条件。若触发条件，公司将于触发条件当日召 开董事会审议决定是否修正转股价格，并及时履行信息披露义务。 根据《上海证券交易所上市公司自律监管指引第 12 号——可转换公司债券》 的有关规定，公司可能触发可转换公司债券（以下简称"可转债"）转股价格向 下修正条件的相关情况公告如下： 一、可转债发行上市概况 经中国证券监督管理委员会证监许可〔2022〕72 号文同意注册，公司于 2022 年 3 月 ...

证券代码：688179 证券简称：阿拉丁 转债代码：118006 转债简称：阿拉转债 上海阿拉丁生化科技股份有限公司 接待投资者调研活动记录 一、机构调研情况 调研时间：2023年11月22日 调研形式：现场交流 参与交流来访的机构投资者： 诺安基金 接待人员： 证券事务代表范依 ...

| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2023-043 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 关于召开 2023 年第三季度业绩说明会的公告 本次投资者说明会以网络互动形式召开，公司将针对 2023 年第三季度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可于 2023 年 11 月 23 日(星期四)至 11 月 29 日(星期三)16:00 前登录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 aladdindmb@163.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 上海阿拉丁生化科技股份有限公司（以下简称"公司"）已于 2023 年 10 月 27 日发布公司 2 ...

Group 1: Company Operations - The second phase of the project has been capped and is undergoing internal renovations, expected to be operational by the end of this year or early next year. The third phase is in process [2] - The company is currently advancing its overseas business, with some orders generated after the overseas website was launched [2] - The company has a dedicated technical service team that provides resources for experts and students, leading to frequent citations of its reagents in high-level publications [2] Group 2: Product Development and Inventory - The total inventory has increased this year, but the structure has changed; older products are seeing slower growth while new product development is accelerating compared to previous years [3] - The company does not plan to phase out existing products but will continue to introduce new ones, as laboratory demand for research reagents remains diverse [2] Group 3: Customer Base and Sales Strategy - The number of university clients has increased as normal teaching and research activities resume, with a notable rise in demand due to recent expansions in graduate student enrollment [3] - The sales strategy for overseas markets will continue to focus on e-commerce and partnerships with distributors [2] Group 4: Internal Assessment Mechanisms - The company conducts annual and semi-annual assessments for management and monthly assessments for employees, with weekly summaries required from each department to address issues promptly [3] Group 5: Disclosure Information - The activity did not involve any significant information that needs to be disclosed [3]

| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2023-042 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 关于注销部分募集资金专项账户的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司在募集资金实际使用过程中，严格按照《募集资金专户存储三方监管协 议》和《募集资金四方监管协议》履行义务，对募集资金的管理和使用进行监督， 保证专款专用。 二、 募集资金管理情况 为规范募集资金的管理和使用，保护投资者利益，本公司根据《公司法》、 《证券法》和《上海证券交易所科创板股票上市规则》等法律、法规的规定和要 求，结合本公司的实际情况，制定了《上海阿拉丁生化科技股份有限公司募集资 金管理制度》。公司对募集资金实行专户存储，公司、子公司、保荐机构已分别 与募集资金监管银行签署《募集资金三方监管协议》和《募集资金四方监管协议》。 截至本次销户前，公司向不特定对象发行可转换公司债券的募集资金专户具 体开户情况如下： | 序号 ...

证券代码：688179 证券简称：阿拉丁 转债代码：118006 转债简称：阿拉转债 上海阿拉丁生化科技股份有限公司 接待投资者调研活动记录 一、机构调研情况 调研时间：2023年10月26日、2023年10月30日 调研形式：线上调研 参与交流来访的机构投资者： 富达基金、高毅资产、国联安基金、中欧基金、汇添富基金、嘉实基金、惠通 基金、浙商证券、中信建投、中信证券、东北证券、长江证券、国盛证券、华 西证券、混沌投资、淡水泉投资、安联保险资产管理有限公司、安信基金、安 ...

Financial Performance - The company's operating revenue for Q3 2023 was ¥97,325,583.17, representing a year-on-year increase of 10.22%[5] - The net profit attributable to shareholders for Q3 2023 was ¥23,772,634.05, a significant increase of 55.58% compared to the same period last year[5] - The net profit excluding non-recurring gains and losses for Q3 2023 was ¥22,074,292.42, up by 50.75% year-on-year[6] - Basic earnings per share for Q3 2023 were ¥0.12, reflecting a 50.00% increase compared to the previous year[6] - Total operating revenue for the first three quarters of 2023 reached ¥282,776,506.57, an increase of 6.4% compared to ¥265,638,354.21 in the same period of 2022[18] - Net profit for the first three quarters of 2023 was ¥54,686,877.69, a decrease of 16.6% from ¥65,538,433.85 in the same period of 2022[19] - Earnings per share for the first three quarters of 2023 were ¥0.28, down from ¥0.33 in the previous year[20] - The company reported a gross profit margin of approximately 59.8% for the first three quarters of 2023, compared to 58.5% in the same period of 2022[18] Research and Development - Total R&D investment for Q3 2023 was ¥12,795,650.70, an increase of 27.69% year-on-year, accounting for 13.15% of operating revenue[6] - Research and development expenses for the first three quarters of 2023 were ¥39,151,361.97, up 46.0% from ¥26,823,728.61 in the same period of 2022[18] - The company plans to continue focusing on product research and development, which has led to an increase in R&D personnel and related costs[10] - The company plans to expand its market presence and invest in new product development in the upcoming quarters[19] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period decreased by 89.31% to -¥5,757,939.53[10] - Cash flow from operating activities for the first three quarters of 2023 was ¥320,407,890.54, an increase of 13.6% compared to ¥281,913,390.28 in the same period of 2022[22] - Cash and cash equivalents decreased to RMB 488,609,297.22 from RMB 570,714,358.62, reflecting a decline of approximately 14.4% year-over-year[15] - Cash inflow from other operating activities was $8.72 million, compared to $16.55 million in the previous quarter[23] - The net increase in cash and cash equivalents was -$82.11 million, contrasting with a net increase of $223.22 million in the previous quarter[24] Assets and Liabilities - The total assets at the end of Q3 2023 were ¥1,479,321,097.24, showing a slight increase of 0.19% from the end of the previous year[6] - Total liabilities as of the end of the third quarter of 2023 amounted to ¥473,721,753.08, a decrease from ¥501,755,013.33 at the end of the previous year[17] - Total equity attributable to shareholders reached ¥1,005,599,344.16, an increase from ¥974,721,715.97 in the previous year[17] - The total current assets decreased to RMB 1,105,512,806.85 from RMB 1,124,088,086.28, showing a decline of about 1.6%[16] - Non-current assets increased to RMB 373,808,290.39 from RMB 352,388,643.02, reflecting an increase of approximately 6.1%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,186[12] - The company reported a total of 945,000 shares held by Shanghai Licheng Asset Management Co., Ltd. through various accounts, indicating significant shareholder engagement[14] - The company has not reported any related party transactions or consistent actions among major shareholders, ensuring transparency in ownership structure[14] Operational Costs - Total operating costs for the first three quarters of 2023 were ¥227,180,142.47, up 16.5% from ¥195,008,847.10 in the previous year[18] - Cash paid for employee compensation increased to $69.52 million from $52.60 million in the previous quarter[23] - Cash paid for taxes rose to $28.38 million, up from $19.69 million in the previous quarter[23] - Cash paid for dividends and interest was $36.96 million, slightly down from $40.38 million in the previous quarter[24]